Aeolus Announces FDA Fast Track Designation Granted to AEOL 10150 for Treatment of Patients With Lung Acute Radiation Syndrome Following a Radiologial or Nuclear Event
June 08, 2017 10:35 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - June 08, 2017) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and...
Aeolus Announces Second Quarter Financial Results for Fiscal Year 2017
May 15, 2017 17:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - May 15, 2017) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and...
AEOL 20415 Protects Lungs Against Infection in Animal Model of Cystic Fibrosis
March 15, 2017 09:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - March 15, 2017) - TREATMENT WITH AEOL 20415 REDUCED INFECTION, IMPROVED BODY WEIGHT AND REDUCED PRESENCE OF WHITE BLOOD CELLS, MACROPHAGES AND LYMPHOCYTESDETAILED...
Aeolus Initiates Phase 1 Study of AEOL 10150 in Healthy Normal Volunteers
February 22, 2017 15:13 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - February 22, 2017) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage...
Aeolus Announces Fiscal Year 2016 Financial Results
December 21, 2016 08:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - December 21, 2016) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage...
Aeolus Announces Publication of Additional Data Demonstrating Efficacy of AEOL 10150 in Sulfur Mustard Exposure in Journal "Toxicological Sciences"
September 19, 2016 09:19 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - September 19, 2016) - TREATMENT WITH AEOL 10150 AFTER EXPOSURE TO SULFUR MUSTARD GAS --IMPROVED SURVIVAL AT 48 HOURS AFTER EXPOSURE FROM 36 PERCENT TO 88...
Aeolus Announces Positive Data Confirming Efficacy of AEOL 10150 as a Medical Countermeasure Against Sulfur Mustard Gas
September 06, 2016 08:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - September 06, 2016) - AEOL 10150 DOUBLED SURVIVAL AT 28 DAYS AFTER EXPOSURE TO LETHAL SULFUR MUSTARD GASMEDIAN SURVIVAL TIME FOR ANIMALS TREATED WITH AEOL 10150 WAS...
Aeolus Pharmaceuticals to Present at Aegis Growth Conference on September 22, 2016
August 31, 2016 09:09 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - August 31, 2016) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage...
Aeolus Announces Third Quarter Fiscal Year 2016 Financial Results
August 15, 2016 16:29 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - August 15, 2016) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage...
Aeolus Pharmaceuticals to Present at LD Micro Invitational Conference
May 23, 2016 08:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - May 23, 2016) -
Aeolus Pharmaceuticals, Inc.
(OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation,...